The Institute for Clinical and Economic Review(ICER) today released a Draft Evidence Report assessing the comparative clinical effectiveness and value of voretigene neparvovec (Spark Therapeutics), a potentially one-time gene therapy for vision loss due to biallelic RPE65-mediated inherited retinal disease.
The report, along with draft voting questions, will be open to public comment for four weeks.
ICER is committed to engaging with all stakeholders in a thorough and transparent manner. Prior to conducting this review, ICER spoke with key patient groups and clinical experts, and accepted public comments on a Draft Scoping Document. The current draft report incorporates input received from patients, clinicians, and other stakeholders during each of these opportunities for engagement.
The Draft Evidence Report and Draft Voting Questions are now open to public comment until 5 p.m. EST Dec. 13. All stakeholders are invited to submit formal comments by email to publiccomments@icer-review.org.
